Larry Biegelsen
Stock Analyst at Wells Fargo
Total Price Targets
48
Stocks Covered
22
Sectors
Healthcare
Most Recent
Feb 26, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Larry Biegelsen
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| MMSI | Merit Medical Systems, Inc. | $78.00 | $62.54 | +24.7% | 4 | Feb 26, 2026 |
| ALC | Alcon Inc. | $97.00 | $74.45 | +30.3% | 4 | Feb 26, 2026 |
| MDT | Medtronic plc | $114.00 | $80.42 | +41.8% | 7 | Jan 30, 2026 |
| ABT | Abbott Laboratories | $122.00 | $89.76 | +35.9% | 2 | Jan 23, 2026 |
| TFX | Teleflex Incorporated | $139.00 | $121.84 | +14.1% | 3 | Dec 10, 2025 |
| EW | Edwards Lifesciences Corporation | $96.00 | $84.24 | +14.0% | 3 | Dec 5, 2025 |
| GEHC | GE HealthCare Technologies Inc. | $87.00 | $61.13 | +42.3% | 1 | Oct 30, 2025 |
| JNJ | Johnson & Johnson | $212.00 | $227.97 | -7.0% | 4 | Oct 3, 2025 |
| NVCR | NovoCure Limited | $14.50 | $16.49 | -12.1% | 2 | Jul 24, 2025 |
| ZBH | Zimmer Biomet Holdings, Inc. | $98.00 | $83.24 | +17.7% | 2 | May 5, 2025 |
| PEN | Penumbra, Inc. | $275.00 | $325.86 | -15.6% | 2 | Dec 11, 2024 |
| ISRG | Intuitive Surgical, Inc. | $466.00 | $459.71 | +1.4% | 2 | Oct 15, 2024 |
| BLCO | Bausch + Lomb Corporation | $23.00 | $16.29 | +41.2% | 1 | Oct 15, 2024 |
| BDX | Becton, Dickinson and Company | $220.13 | $149.07 | +47.7% | 2 | Aug 2, 2024 |
| GKOS | Glaukos Corporation | $120.00 | $142.00 | -15.5% | 1 | Jun 3, 2024 |
| HYPR | Hyperfine, Inc. | $1.60 | $1.84 | -13.0% | 2 | Mar 22, 2024 |
| NPCE | NeuroPace, Inc. | $20.00 | $17.04 | +17.4% | 1 | Mar 14, 2024 |
| TNDM | Tandem Diabetes Care, Inc. | $49.00 | $19.34 | +153.4% | 1 | Aug 9, 2022 |
| DXCM | DexCom, Inc. | $35.94 | $61.51 | -41.6% | 1 | Jan 19, 2022 |
| COO | The Cooper Companies, Inc. | $480.00 | $62.51 | +667.9% | 1 | Aug 19, 2021 |
| BSX | Boston Scientific Corporation | $52.50 | $56.91 | -7.7% | 1 | Aug 1, 2021 |
| IART | Integra LifeSciences Holdings Corporation | $74.00 | $10.85 | +582.0% | 1 | Apr 29, 2021 |
Recent Activity
- Feb 26, 2026— Set$97.00price target onALC(Alcon Inc.)
- Feb 26, 2026— Set$78.00price target onMMSI(Merit Medical Systems, Inc.)
- Jan 30, 2026— Set$114.00price target onMDT(Medtronic plc)
- Jan 23, 2026— Set$122.00price target onABT(Abbott Laboratories)
- Dec 10, 2025— Set$139.00price target onTFX(Teleflex Incorporated)
- Dec 5, 2025— Set$96.00price target onEW(Edwards Lifesciences Corporation)
- Oct 30, 2025— Set$87.00price target onGEHC(GE HealthCare Technologies Inc.)
- Oct 3, 2025— Set$212.00price target onJNJ(Johnson & Johnson)
- Jul 24, 2025— Set$14.50price target onNVCR(NovoCure Limited)
- May 5, 2025— Set$98.00price target onZBH(Zimmer Biomet Holdings, Inc.)
- May 2, 2025— Set$137.00price target onTFX(Teleflex Incorporated)
- Apr 25, 2025— Set$106.00price target onMMSI(Merit Medical Systems, Inc.)
- Dec 11, 2024— Set$275.00price target onPEN(Penumbra, Inc.)
- Oct 15, 2024— Set$23.00price target onBLCO(Bausch + Lomb Corporation)
- Oct 15, 2024— Set$166.00price target onJNJ(Johnson & Johnson)
- Oct 15, 2024— Set$466.00price target onISRG(Intuitive Surgical, Inc.)
- Sep 16, 2024— Set$103.00price target onMMSI(Merit Medical Systems, Inc.)
- Sep 9, 2024— Set$80.00price target onEW(Edwards Lifesciences Corporation)
- Aug 22, 2024— Set$105.00price target onALC(Alcon Inc.)
- Aug 21, 2024— Set$106.00price target onMDT(Medtronic plc)
Frequently Asked Questions
Who is Larry Biegelsen?
Larry Biegelsen is a stock analyst at Wells Fargo covering 22 stocks primarily in Healthcare. They have issued 48 price targets since Apr 29, 2021.
What stocks does Larry Biegelsen cover?
Larry Biegelsen currently covers 22 stocks, including MDT, MMSI, ALC, JNJ, TFX.
What is Larry Biegelsen's latest price target?
Larry Biegelsen's most recent price target was $97.00 on ALC (Alcon Inc.), set on Feb 26, 2026.
What is Larry Biegelsen's highest price target?
Larry Biegelsen's highest issued price target is $480.00 on COO, set on Aug 19, 2021.
More Analysts at Wells Fargo
Coverage based on publicly published price targets. Not investment advice.